Copyright
©The Author(s) 2020. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Stem Cells. Jul 26, 2020; 12(7): 688-705
Published online Jul 26, 2020. doi: 10.4252/wjsc.v12.i7.688
Published online Jul 26, 2020. doi: 10.4252/wjsc.v12.i7.688
Mesenchymal stem cells and mesenchymal stem cell-derived extracellular vesicles: Potential roles in rheumatic diseases
Jing-Han Yang, Jing-Hua Wang, Dong-Hua Xu, Central Laboratory of the First Affiliated Hospital, Weifang Medical University, Weifang 261000, Shandong Province, China
Jing-Han Yang, Jing-Hua Wang, Dong-Hua Xu, Department of Rheumatology of the First Affiliated Hospital, Weifang Medical University, Weifang 261000, Shandong Province, China
Feng-Xia Liu, Department of Allergy, Weifang People’s Hospital, Weifang 261000, Shandong Province, China
Min Cheng, Department of Physiology, Weifang Medical University, Weifang 261000, Shandong Province, China
Shu-Feng Wang, Medical Experimental Training Center, Weifang Medical University, Weifang 261000, Shandong Province, China
Author contributions: Yang JH collected the data and drafted this manuscript; Liu FX collected the data and revised the draft; Wang JH collected the data; Cheng M revised the Prisma 2009 and the references; Wang SF proposed some discussions in this work; Xu DH designed the systematic review and performed the data analysis; all authors read and approved the final manuscript.
Supported by National Natural Science Foundation of China , No. 81601408 .
Conflict-of-interest statement: The authors have no potential conflicts of interests to declare.
PRISMA 2009 Checklist statement: The authors have read the PRISMA 2009 Checklist, and the manuscript was prepared and revised according to the PRISMA 2009 Checklist.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Corresponding author: Dong-Hua Xu, MD, PhD, Doctor, Research Scientist, Central Laboratory of the First Affiliated Hospital and Department of Rheumatology of the First Affiliated Hospital, No. 2428 Yuhe Road, Kuiwen District, Weifang Medical University, Weifang 261000, Shandong Province, China. flower322@163.com
Received: March 4, 2020
Peer-review started: March 4, 2020
First decision: April 18, 2020
Revised: May 26, 2020
Accepted: June 10, 2020
Article in press: June 10, 2020
Published online: July 26, 2020
Processing time: 144 Days and 5.4 Hours
Peer-review started: March 4, 2020
First decision: April 18, 2020
Revised: May 26, 2020
Accepted: June 10, 2020
Article in press: June 10, 2020
Published online: July 26, 2020
Processing time: 144 Days and 5.4 Hours
Core Tip
Core tip: Mesenchymal stem cells (MSCs) and MSC-derived extracellular vesicles (EVs) have long been thought to possess considerable immunomodulatory and regenerative potential. Rheumatic disease is a group of diseases marked by immune dysregulation and chronic progressive inflammation. Targeting MSCs and MSC-derived EVs may be a more efficient treatment for rheumatic diseases. However, before their application in the clinical treatment, a large number of preclinical studies and clinical studies are required to thoroughly assess their safety and efficiency. This work summarizes current advances and offers a strong basis for the next study of MSCs and MSC-derived EVs in this field.